Drugs / HLX10, Trastuzumab and Chemotherapy
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05311189 | Apr 2022 → Dec 2023 | carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX10, Trastuzumab and Chemotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05311189 ↗ |
| Route | Oral | “S1 40mg/m2, PO” NCT05311189 ↗ |